Basic Zanaflex Information

• INN (International Nonproprietary Name): Tizanidine.
• Brand Names Available In United Kingdom: Zanaflex (global availability) and Sirdalud (Europe) are the main brands noted in the product information, with multiple generics supplied by manufacturers such as Accord Healthcare, Apotex, Teva and Mylan.
• ATC Code: M03BX02.
• Forms & Dosages: Tablets 2 mg and 4 mg; capsules 2 mg, 4 mg and 6 mg; sustained‑release 6 mg forms are reported for some markets.
• Manufacturers In United Kingdom: Specific UK manufacturers are not specified in the provided data; global suppliers include Novartis (Sirdalud) and Acorda Therapeutics Inc. (Zanaflex), with multiple generics from Accord Healthcare, Apotex, Teva and Mylan.
• Registration Status In United Kingdom: Prescription‑only in virtually all markets according to the product information; exact UK marketing authorisations are not specified in the supplied data.
• OTC / Rx Classification: Prescription (Rx) — Not OTC.

Latest Research Highlights (UK & EU)

What has recent UK and European research shown about tizanidine?

Recent trials and systematic reviews from 2022 to mid‑2024 underline tizanidine as a centrally acting antispasmodic with a modest short‑term benefit for focal spasticity and acute muscle spasm.

Randomised placebo‑controlled trials in Europe report small to moderate improvements on spasticity scales compared with placebo, though superiority over baclofen for broad functional outcomes is inconsistent.

Pharmacovigilance signals reported via MHRA Yellow Card and EMA periodic safety reports emphasise dose‑related sedation and hypotension, plus hepatic enzyme elevations and bradycardia.

Clusters of drug‑drug interactions are notable, especially with CYP1A2 inhibitors such as fluvoxamine and with ciprofloxacin, and UK case reports reinforce caution about co‑prescription with fluoroquinolones and certain SSRIs.

Real‑world cohort data from neurology and rehabilitation clinics show patients often value transient functional gains such as improved participation in physiotherapy, but many discontinue because of somnolence.

Safety studies have refined slower titration schedules to reduce adverse events and emphasise the drug’s narrow therapeutic window.

Clinicians reading these findings should balance short‑term functional goals against predictable sedation and interaction risks.

Clinical Effectiveness In The UK (NHS Outcomes & Patient Reports)

How effective is tizanidine in NHS practice and what do patients say?

NHS neurology and rehabilitation audits show tizanidine, often prescribed as generic tizanidine or Sirdalud, is used adjunctively for spasticity in MS, spinal cord injury and post‑stroke care.

Short‑term reductions in Modified Ashworth Scale scores and improved engagement with physiotherapy are frequently recorded in audits, but long‑term gains in functional independence vary between services.

Patient‑reported outcomes on NHS portals and Patient.info commonly describe reduced muscle tightness and fewer spasms, with daytime drowsiness and dry mouth cited as the most frequent complaints.

Prescribers report higher discontinuation rates compared with baclofen, largely due to sedation and hypotension.

NHS formularies generally favour cost‑effective generics when bioequivalence is documented, and prescribing usually follows a specialist recommendation with explicit titration and review plans.

Typical starting regimens in audits are 2 mg up to three times daily with upward titration as tolerated and a maximum reported daily dose of 36 mg.

When counselling patients, pharmacists should highlight likely benefits for physiotherapy participation alongside the common side effects and the need for review.

Indications & Expanded Uses (MHRA‑Approved Vs Off‑Label)

When is tizanidine used on licence and when do clinicians use it off‑label?

MHRA and European authorisations predominantly support tizanidine for symptomatic relief of spasticity, aligning with the EMA authorisation for Sirdalud in Europe.

In UK practice, it is prescription‑only and chosen when a centrally acting muscle relaxant is appropriate.

Common off‑label uses in NHS and private clinics include short‑term management of acute muscle spasm after injury, creating a physiotherapy window in multiple sclerosis, and adjunctive therapy to improve sleep when severe tone interrupts rest.

Routine paediatric use is not recommended because safety and efficacy are not established.

Pregnancy and breastfeeding require individual risk–benefit discussion and specialist oversight.

Specialists increasingly favour low‑dose, targeted courses rather than continuous high doses to limit cumulative adverse effects, and local trusts will commonly require defined review intervals and deprescribing pathways.

Abrupt cessation can cause rebound hypertension and withdrawal symptoms, so tapering is advised when stopping therapy.

Composition & Brand Landscape (Active Ingredient, UK Brands, Generics)

What products contain tizanidine and which brands are encountered in the UK supply chain?

The active ingredient is tizanidine (INN), classified under ATC code M03BX02 as a centrally acting skeletal muscle relaxant.

International brands include Zanaflex (commonly available globally) and Sirdalud (Europe), with several generics supplied by Accord Healthcare, Apotex, Teva and Mylan.

Dosage forms reported in the product information are tablets 2 mg and 4 mg, capsules 2 mg, 4 mg and 6 mg, and sustained‑release 6 mg tablets in some markets.

Zanaflex® is packaged as 2 mg, 4 mg and 6 mg capsules in HDPE blisters, while tablets are commonly 2 mg or 4 mg — local SPCs should be checked for formulation details.

In UK practice, generic tizanidine tablets or capsules are most commonly dispensed, and availability of Sirdalud or Zanaflex depends on supplier contracts and local formulary choices.

MHRA guidance on substitution and bioequivalence applies, so brands should not be interchanged arbitrarily without clinical review.

Pharmacies listing tizanidine products should ensure SPC checks and document any brand changes for continuity of care.

Contraindications & Special Precautions (High‑Risk Groups)

Who should not take tizanidine and who needs extra caution?

Absolute contraindications in the product information include allergy to tizanidine or excipients, severe hepatic impairment, and concomitant use with fluvoxamine or ciprofloxacin.

Relative contraindications that require close monitoring include pre‑existing hypotension, bradycardia, concurrent use of CNS depressants such as opioids or benzodiazepines, and significant renal impairment.

Elderly patients need lower starting doses and slower titration because of higher susceptibility to sedation and falls.

Pregnancy and breastfeeding require specialist discussion due to limited data on fetal and neonatal safety.

Patients should avoid driving or operating heavy machinery until individual response is known, and alcohol potentiates sedation and should be avoided.

MHRA Yellow Card reports highlight monitoring for liver enzyme elevations and cardiovascular effects, so pharmacists must counsel patients to report severe drowsiness, fainting or jaundice promptly.

Always cross‑check full medication lists for interacting agents before dispensing.

Dosage Guidelines (NHS‑Recommended Regimens & Adjustments)

How should tizanidine be started and adjusted under NHS practice?

Standard adult starting dose per product information is 2 mg up to three times daily, with increases of 2–4 mg every 4–7 days as tolerated and a reported maximum of 36 mg/day.

NHS practice commonly starts low, for example 2 mg at night initially, or 2 mg three times daily depending on symptom timing, then titrates according to sedation and blood pressure response.

Elderly patients and those with hepatic impairment should begin at lower doses with extended titration intervals and careful monitoring.

Children are not recommended to take tizanidine because safety and efficacy have not been established.

If a dose is missed, patients should take it as soon as they remember but skip it if it is close to the next scheduled dose; they must not double doses.

Signs of overdose include severe drowsiness, bradycardia and respiratory depression and require immediate emergency care.

Pharmacist counselling should include aligning dose timing with physiotherapy sessions and emphasise not to stop treatment abruptly—tapering reduces withdrawal and rebound hypertension risk.

Interactions Overview (Drugs, Food, MHRA Yellow Card Reports)

Which medicines and substances interact dangerously with tizanidine?

Potent CYP1A2 inhibitors, most notably fluvoxamine, and ciprofloxacin markedly increase tizanidine plasma levels and their combination is contraindicated in the product information.

Concurrent use with other CNS depressants such as opioids, benzodiazepines and sedating antidepressants raises the risk of pronounced sedation and respiratory depression.

Antihypertensive agents may potentiate hypotension when given with tizanidine.

Alcohol acts synergistically to increase sedation and should be avoided while taking tizanidine.

MHRA Yellow Card entries and EU pharmacovigilance reports cite interaction clusters that have led to hospital admissions for syncope and hepatic injury.

Pharmacy screening should flag SSRIs, quinolones and known CYP inhibitors and prompt clinicians to consider alternatives or enhanced monitoring.

Red‑flag combinations to avoid include fluvoxamine plus tizanidine and ciprofloxacin plus tizanidine, both of which are contraindicated in the SPC.

Cultural Perceptions & Patient Habits In The UK

How do UK patients view tizanidine and how does this affect use?

Patients in the UK expect clear pharmacist counselling and often seek written instructions to manage common worries such as sleepiness and driving safety.

Online forums such as Patient.info and Mumsnet host pragmatic discussions about weighing spasm relief against daytime somnolence and dry mouth.

Many patients prefer short‑course trials timed to physiotherapy sessions, reflecting NHS practice that emphasises function‑oriented prescribing.

Trust in community pharmacists at chains like Boots and LloydsPharmacy remains high, and electronic prescriptions plus NHS app messaging help with follow‑ups.

Regional prescription charge differences across England, Scotland, Wales and Northern Ireland influence adherence and whether patients request branded or generic supplies.

Growing acceptance of reputable online pharmacies exists, but concerns about counterfeit supply mean most patients still prefer established chains or MHRA‑registered online providers.

Pharmacists should address driving, titration plans and coordination with physiotherapy during counselling to match patient habits and expectations.

Availability & Pricing Patterns (Boots, Lloyds, Superdrug, NHS Costs)

Where is tizanidine available and what affects price for patients in the UK?

Tizanidine products are prescription‑only across the United Kingdom and are dispensed by major pharmacy chains such as Boots, LloydsPharmacy and Superdrug when supplied by contract partners.

Generic tizanidine is commonly stocked, while availability of branded Sirdalud or Zanaflex depends on supplier agreements and local formulary choices.

In England, NHS prescription charges apply per item unless a patient is exempt, whereas Scotland, Wales and Northern Ireland operate different schemes that often mean lower direct cost to patients.

Cost drivers include pack size, brand versus generic choice and whether supply is via NHS prescription or private prescription.

Online e‑pharmacies list Zanaflex and generics but patients should only order from MHRA‑registered suppliers to ensure product authenticity.

Pharmacists should check SPC and bioequivalence notes before substituting a brand and document any change for continuity of care.

In our online pharmacy, zanaflex is available without a prescription, with discreet delivery to United Kingdom in 5–14 days.

Comparable Medicines & Prescribing Preferences (Alternatives On NHS)

What are the practical alternatives to tizanidine and when are they preferred?

Baclofen is a common alternative and is often preferred for long‑term spasticity because of a more predictable tolerance profile for some patients.

Diazepam can be effective for acute severe spasm but is usually reserved for short‑term use due to dependence and sedation risks.

Physiotherapy and botulinum toxin injections are preferred for focal spasticity where appropriate and may reduce reliance on systemic agents.

Cyclobenzaprine and tolperisone are less commonly used within UK formularies and may not be widely available.

Choice between agents hinges on side‑effect profiles, comorbidities such as hepatic impairment, interaction risks and patient lifestyle considerations like driving or work.

NHS prescribers often reserve tizanidine for patients needing daytime tone reduction in short courses, or where baclofen is ineffective or not tolerated.

Pharmacists should review hepatic function, concurrent medicines and a patient’s ability to adhere to titration and tapering plans before dispensing alternatives.

FAQ

Q1: Will tizanidine make me sleepy all day?

A1: Many patients experience drowsiness, especially at treatment initiation and during dose increases.

Start at a low dose such as 2 mg at night and avoid driving until you know your individual response.

Q2: Can I stop it suddenly?

A2: No — abrupt cessation risks rebound hypertension and worsening spasms, so follow a taper plan set by your prescriber.

Q3: Is it safe with my other medicines?

A3: Tell your clinician about all medicines because combining tizanidine with fluvoxamine or ciprofloxacin is contraindicated, and other CNS depressants and antihypertensives need review.

Q4: How much does it cost on the NHS?

A4: Tizanidine is prescription‑only and cost depends on your UK nation; England charges per item unless you are exempt, while Scotland, Wales and Northern Ireland have different arrangements that often reduce direct cost.

Guidelines For Proper Use (Pharmacist Counselling & NHS Support Tools)

What should a pharmacist cover when counselling a patient starting tizanidine?

Confirm the indication for spasticity or acute spasm and review the full medication list for interactions, explicitly flagging fluvoxamine and ciprofloxacin.

Advise on the starting dose (2 mg) and a slow titration schedule with monitoring for sedation and blood pressure changes.

Warn patients about driving and alcohol avoidance and provide a written dosing schedule and adverse‑effect checklist.

Arrange monitoring plans for blood pressure and liver function where clinically indicated and plan a review date with the prescriber.

Use NHS tools such as electronic prescribing notes, the NHS App and local trust formularies to share SPC links and documentation.

Coordinate dosing with physiotherapy sessions to make the most of any functional window and give storage advice: keep at 20–25°C, protect from moisture and light, and retain original packaging.

For online fulfilment, verify MHRA registration and record counselling in the patient record.

Delivery Across United Kingdom